Aktie A2N4R0 ENTASIS THERAPEUTICS HOLDINGS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Entasis Therapeutics Holdings Inc.

Aktien

A2N4R0

US2936141033

ETTX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index
Innoviva Acquires Remaining Stake in Entasis Therapeutics
Entasis Therapeutics : Termination of a Material Definitive Agreement - Form 8-K
ENTASIS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
Entasis Therapeutics : Innoviva to Acquire Entasis Therapeutics - Form 8-K
ENTASIS THERAPEUTICS HOLDINGS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell
Innoviva to Acquire Entasis Therapeutics
Innoviva to Acquire Entasis Therapeutics
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N4R0 Aktie
  4. Nachrichten Entasis Therapeutics Holdings Inc.
  5. Andere Sprachen